Effectiveness of combinations of Ayurvedic drugs in alleviating drug toxicity and improving quality of life of cancer patients treated with chemotherapy
- 362 Downloads
This study was conducted to assess the effectiveness of combinations of Ayurvedic drugs in alleviating the toxicity of chemotherapy and improving the quality of life of cancer patients. The following was the research question: Can Ayurvedic drugs be used to alleviate the side effects of chemotherapy and improve the quality of life of cancer patients?
Random patients with malignancies of different tissues, grades, and stages were divided into two groups according to their treatment modality. Group 1 consisted of 15 patients treated with six cycles of chemotherapy alone and who did not receive any Ayurvedic drugs (control group). Group 2 consisted of patients (divided into three arms) who received Ayurvedic drugs during chemotherapy and after chemotherapy. Nineteen patients in arm 1 received the Ayurvedic drugs Mauktikyukta Kamdudha (MKD) and Mauktikyukta Praval Panchamruta (MPP) along with a full course of chemotherapy. Fifteen patients in arm 2 received the same Ayurvedic treatment, but the treatment was started after completing the sixth cycle of chemotherapy. Eighteen patients in arm 3 received the Suvarnabhasmadi formulation (SBD) in addition to MKD and MPP after completing the sixth cycle of chemotherapy. Treatment was given for 16 weeks in all three arms. Patients from both groups were observed for a period of 6 months. The assessment criteria depended on Common Toxicity Criteria (CTC designed by NIH and NCI): haemogram; weight; physical examination including Quality of Life Questionnaire (QLQ designed by the European Organization of Research and Treatment of Cancer (EORTC)) for functional, symptom and global scores; and Karnofsky score for assessment of general well-being and activities of daily life. ECOG (Eastern Cooperation Oncology Group) score was also additionally included for assessment of symptoms.
From amongst the symptomatic criteria, there was significant improvement in all the three arms compared with the control group in nausea, loss of appetite, constipation, and fatigue. There was significant improvement in the Karnofsky score and global score of the QLQ, which in fact incorporate symptomatic criteria, general condition, functional ability and disease-related symptoms. These significant differences were observed in group 2 (arms 1, 2, 3) in comparison with group 1 (control), in spite of the fact that in arms 2 and 3, the Ayurvedic treatment was started after completion of chemotherapy. The haemogram did not show a significant difference between the control and the three arms of group 2.
Adjunct treatment with herbo-mineral and metallic Ayurvedic drugs appears to have a significant effect on reducing the toxic side effects of chemotherapy drugs in cancer patients. Our preliminary data suggests that Ayurvedic treatment should be given simultaneously from the beginning of chemotherapy to have the desired effect. However, there is a need to extend this work by conducting a well-planned two-armed study on cancer patients with defined cancer sites with selected Ayurvedic drug combinations, and observing the patients for a longer period of time to confirm the effectiveness of Ayurvedic drugs in reducing the side effects of chemotherapy.
KeywordsToxicity of anti-cancer drugs Quality of life Ayurvedic drugs Mauktikyukta Kamadudha Mauktikyukta Praval Panchamrut Suvarnabhasmadi formulation
We acknowledge the respected P.K. Sardeshmukh Maharaj, Founder Trustee of Bharatiya Sanskriti Darshan Trust and originator of the Cancer Research Project of the trust. We also wish to acknowledge Mr. D.V. Jogalekar, formerly statistician at BIAF, Development Research Foundation, Pune, India, for his excellent input in the statistical analysis of our data. Mr. Shyam Shitole is acknowledged for his help in the graphics and designing of the figures.
Conflict of interest
The group of our research fellows, namely Dr. S. Gore, Dr. R. Nimbalkar, Dr. D. Deshpande, Dr, S. Chavan, Dr. S. Agashe, Dr. K. Karle, Dr. S. Mujawar, Dr. A. Mujawar, Dr. N. Patil, Dr. V. Awalkanthe, Dr. A. Patre, Dr. A. Salunkhe, Dr. A.A. Salunkhe, Dr. J. Kambale, Dr. A. Shingate and Dr. M. Madne, are acknowledged for meticulously conducting patients’ data collection, tests for criteria at four time points of patients included (and excluded), counselling and filling of the questionnaire.
The rights will remain with the publisher.
- 1.Vincent T, Lawrence T, Rosenberg S (2008) Cancer: Principles & Practice of Oncology, 8th edn. In: Devita, Hellman, Rosenberg (eds) Rehabilitation of the cancer patient. Publ. Lippincott Williams & Wilkins, pp 2858–2859Google Scholar
- 6.Tripathi B (2003) Charak Samhita, vol. 2, Chaukhamba Surabharati Prakashan, Varanasi, Rasayana 1/1/4, p. 3Google Scholar
- 7.Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, May 2009 (updated June 2010) U.S. Department Of Health and Human Services NIH, NCI http://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
- 8.Vincent T, Lawrence T, Rosenberg S (2008) Cancer: Principles & Practice of Oncology, 8th edn. In: Devita, Hellman, Rosenberg (eds) Rehabilitation of the cancer patient. Publ. Lippincott Williams & Wilkins, pp 2958–2959Google Scholar
- 10.Vaidya B (1999) Nighantu Adarsha, part −2, 2nd edn. Chaukhamba Publications, pp 636–641Google Scholar
- 11.Vaidya B (1999) Nighantu Adarsha, part −2, 2nd edn. Chaukhamba Publications, pp 19–25Google Scholar
- 12.Vaidya B (1999) Nighantu Adarsha, Part −2, 2nd edn. Chaukhamba publications, pp 134–141Google Scholar
- 13.Vaidya B (1999) Nighantu Adarsha, part −2, 2nd edn. Chaukhamba Publications, pp 403–441Google Scholar
- 14.Sharma HP, Rasayogasagar. Part −2, Krishnadas Ayurved Series, p 93Google Scholar
- 15.Sharma HP, Rasayogasagar. Part −1, Krishnadas Ayurved Series, p 260Google Scholar
- 17.Dubey N, Mehta R, Saluja A, Jain D (2009) Antiulcer activity of a traditional pearl preparation: Mukta Bhasma Research. J Pharm Technol 2:287–290Google Scholar
- 19.Van den Bent MJ, Grisold W, Frappaz D, Stupp R, Desir JP, Lesimple T, Dittrich C, de Jonge MJ, Brandes A, Frenay M, Carpentier AF, Chollet P, Oliveira J, Baron B, Lacombe D, Schuessler M, Fumoleau P (2003) European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastomamultiforme. Ann Oncol 14:1732–1734PubMedCrossRefGoogle Scholar
- 20.Cancer Care Ontario (CCO) Drug formulary, updated in 2013 www.cancercare.on.ca/toolbox/drugs/drugformulary
- 22.1995 EORTC Quality of Life Group. Version 3.0 http://groups.eortc.be/qol/eortc-qlq-c30
- 23.Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376PubMedCrossRefGoogle Scholar
- 26.Dercksen MW, Hoekman, Ten Bokkel Huinink WW, Rankin EM, Dubbelman R, Tinteren H, Wagstaff J, Pinedo H (1993) Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours. Br J Cancer 68:996–1003. doi: 10.1038/bjc. 1993.468 PubMedCrossRefPubMedCentralGoogle Scholar
- 27.Deshmukh V, Sardeshmukh S (2006) To study the effect of Suvarnabhasmadi Yoga & Guduchi Siddha Kshirapak in the treatment of Aupasargik Rajayakshma—Shosha Vyadhi (HIV+ve patients). Dissertation, University of Pune, Maharashtra, IndiaGoogle Scholar
- 28.Mamgani A, Rooji PV, Tans L, Verduijn GM, Sewnaik A, Jong RB (2013) A prospective evaluation of patient-reported quality-of-life after (chemo) radiation for oropharyngeal cancer: which patients are at risk of significant quality-of-life deterioration? Radiother Oncol 106:359–363CrossRefGoogle Scholar
- 29.Kulkarni D (1981) Ayurvediya Rasaushadhi Nirman, 1st ed, Continental Publications, p 283Google Scholar